Cadrenal Therapeutics, Inc. CVKD

CVKD Company Overview

Cadrenal Therapeutics, Inc. (NASDAQ: CVKD) is a biopharmaceutical company focused on the development and commercialization of therapeutics for cardiovascular diseases and rare cardiovascular conditions. The company’s primary emphasis is on advancing anticoagulant therapies intended to address unmet medical needs in patients requiring chronic anticoagulation treatment. Cadrenal operates within the biotechnology and specialty pharmaceutical industries, with a strategic focus on late-stage or previously developed assets that may be advanced through regulatory pathways with targeted clinical development.

The company’s principal asset is tecarfarin, an oral vitamin K antagonist anticoagulant designed to provide a potential alternative to warfarin for patients with end-stage kidney disease and other populations where drug-drug interactions and metabolic variability may complicate treatment. Cadrenal has positioned tecarfarin as a differentiated therapy candidate due to its metabolism pathway, which is largely independent of the CYP450 enzyme system commonly associated with interactions affecting warfarin. Cadrenal Therapeutics was formed through a corporate reorganization and public market transaction completed in 2022, after which the company concentrated its strategy on cardiovascular therapeutics development and regulatory advancement.